Comparative Study of Sublingual and Vaginal Misoprostol in Second Trimester Induced Abortion

DOI: 10.4236/ojog.2014.413104   PDF   HTML     2,611 Downloads   3,296 Views   Citations


Background: To identify an effective misoprostol-only regime for the termination of second trimester pregnancy. Objectives: To compare the efficacy, safety and acceptability of sublingual and vaginal misoprostol for second trimester pregnancy termination. Methods: In a prospective randomized comparative study, over 138 pregnant women at 13 - 20 weeks (91 - 140 days) of gestation requiring medical abortion were randomly assigned to the sublingual or vaginal route for misoprostol administration with dose schedule of 400 mcg every 3 hours up to 5 doses within 24 hours. The course of misoprostol was repeated if the woman did not abort within 24 hours. Primary outcome was the efficacy of the treatment to terminate pregnancy completely at 24 and 48 hours. Secondary outcomes measured were induction-abortion interval, side effects, failure rate, and women’s perception to these treatments. Results: At 24 h, the complete abortion rate was 87.88% in the vaginal administration group and 79.41% in sublingual group (difference 8.5%, 95% CI: 3.8 to 13.2). No significant difference in the complete abortion rates was observed at 48 h(90.91% versus 88.24% difference: 2.7%, 95% CI: ?0.04 to 5.4) when vaginal and sublingual groups were compared. Mean induction-abortion interval in sublingual and vaginal groups was 12.28 h (95% CI of mean 11.019 - 13.541 h) and 13.11 h (95% CI of mean 12.0301 - 14.1899 h) respectively; p = 0.485. The rates of side effects were similar in both groups except for fever, which was more common in vaginal group. Significantly more women in the sublingual group preferred the route as compared to vaginal administration (RR 1.618. 95% CI: 1.277 - 2.050; p < 0.0001). Conclusion: Both sublingual and vaginal routes of misoprostol are equally effective in medical termination of pregnancy in second trimester but sublingual route was preferred by the women.

Share and Cite:

Modak, R. , Biswas, D. , Ghosh, A. , Pal, A. and Mandal, T. (2014) Comparative Study of Sublingual and Vaginal Misoprostol in Second Trimester Induced Abortion. Open Journal of Obstetrics and Gynecology, 4, 751-756. doi: 10.4236/ojog.2014.413104.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] World Health Organization (1997) Medical Methods for Termination of Pregnancy: Report of a WHO Scientific Group. Who Technical Report Series No. 871, World Health Organization, Geneva.
[2] Tietza, C. (1981) Second-Trimester Abortion: A Global View. In: Berger, G.S., Berger, W.E., Keith, L.G., Eds., Second-Trimester Abortion, John Wright, Boston, 1-11.
[3] Gomez Ponce de Leon, R. and Wing, D.A. (2009) Misoprostol for Termination of Pregnancy with Intrauterine Fetal Demise in the Second and Third Trimester of Pregnancy—A Systematic Review. Contraception, 79, 259-271.
[4] El-Rafaey, H. and Templeton, A. (1995) Induction of Abortion in the Second Trimester by a Combination of Misoprostol and Mifepristone: A Randomized Comparison between Two Misoprostol Regimens. Human Reproduction, 10, 475-478.
[5] Ho, P.C., Chan, Y.E. and Lau, W. (1996) Misoprostol Is as Effective as Gemeprost in Termination of Second Trimester Pregnancy When Combined with Mifepristone: A Randomized Comparative Trail. Contraception, 53, 281-283.
[6] Wong, K.S., Ngai, C.S.W., Yeo, E.L.K. and Tang, L.C.H. (2000) A Comparison of Two Regimens of Intravaginal Misoprostol for Termination of Second Trimester Pregnancy: A Randomized Comparative Trail. Human Reproduction, 15, 709-712.
[7] Zieman, M., Fong, S.K., Benowitz, N.L., Banskter, D. and Darney, P.D. (1997) Absorption Kinetics of Misoprostol with Oral or Vaginal Administration. Obstetrics & Gynecology, 90, 88-92.
[8] Tang, O.S., Schweer, H., Seyberth, H.W., Lee, S.W.H. and Ho, P.C. (2002) Pharmacokinetics of Different Routes of Administration of Misoprostol. Human Reproduction, 17, 332-336.
[9] Meckstroth, K.R., Whitaker, A.K., Bertisch, S., et al. (2006) Misoprostol Administered by Epithelial Routes: Drug Absorption and Uterine Response. Obstetrics & Gynecology, 108, 582-590.
[10] Ho, P.C., Ngai, S.W., Liu, K.L., Wong, G.C. and Lee, S.W. (1997) Vaginal Misoprostol Compared with Oral Misoprostol in Termination of Second Trimester Pregnancy. Obstetrics & Gynecology, 90, 735-738.
[11] Ngai, S.W., Tang, O.S. and Ho, P.C. (2003) Prostaglandins for Induction of Second Trimester Termination and Intrauterine Death. Best Practice Research Clinical Obstetrics Gynaecology, 17, 765-775.
[12] El-Refeay, H., Hinshaw, K. and Templeton, A. (1993) The Abortifacient Effect of Misoprostol in Second Trimester. A Randomized Comparison with Gemeprost in Patients Pretreated with Mifepristone (RU486). Human Reproduction, 8, 1744-1746.
[13] Tang, O.S., Lau, W.N.T., Chan, C.C.W. and Ho, P.C. (2004) A Prospective Randomized Comparison of Sublingual and Vaginal Misoprostol in Second Trimester of Pregnancy. BJOG, 111, 1001-1005.
[14] Bhattacharjee, N., Saha, S.P., Ghoshroy, S.C., Bhowmik, S. and Barui, G. (2008) A Randomised Comparative Study on Sublingual versus Vaginal Administration of Misoprostol for Termination of Pregnancy between 13 to 20 Weeks. Australian and New Zealand Journal of Obstetrics and Gynaecology, 48, 165-171.
[15] Hertzen, H.V., Piaggio, G., Wojdyla, D., Huong, N.T.M., Marions, L. and Okeov, G. (2009) Comparison of Vaginal And Sublingual Misoprostol for Second Trimester Abortion: Randomized Controlled Equivalence Trial. Human Reproduction, 24, 106-112.
[16] Ganguly, R.P., Saha, S.P., Mukhopadhyay, S., Bhattacharjee, N., Bhattacharyya, S.K. and Patra, K.K. (2010) A Comparative Study on Sublingual Versus Oral and Vaginal Administration of Misoprostol for Late First and Early Second Trimester Abortion. Journal of the Indian Medical Association, 108, 283-286.

comments powered by Disqus

Copyright © 2020 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.